Clinical Trial Detail

NCT ID NCT03704077
Title An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Trherapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cance or Gastroesophageal Junction Adenocarcinoma
Recruitment Withdrawn
Gender both
Phase Phase II
Variant Requirements No
Sponsors Bristol-Myers Squibb
Indications

gastroesophageal junction adenocarcinoma

stomach cancer

Therapies

Nivolumab

Paclitaxel + Ramucirumab

Nivolumab + Paclitaxel

Nivolumab + Paclitaxel + Relatlimab

Nivolumab + Relatlimab

Age Groups: adult senior

No variant requirements are available.